The Role of 68Ga FAPI-04 and 18F-FDG PET/CT in Detecting Liver Metastases in Different Types of Cancer

Abstract

Objective We compared the diagnostic accuracies of 68Ga FAPI-04 PET/CT and 18F-FDG PET/CT for detecting liver metastases (LMs) in patients with different cancer types. Materials and Methods This retrospective study included 63 patients with liver lesions who underwent 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT between May 2020 and May 2022. Patients with histopathologically confirmed primary diagnoses, data that could be accessed retrospectively, liver lesions confirmed by biopsy over at least 3–6 months of follow-up (via ultrasonography, CT, magnetic resonance imaging, PET/CT, or laboratory tests) were included. Patients with secondary malignancies or primary liver malignancies, and/or who could not be followed-up, were excluded. Results Of the 63 total patients, 34 (54%) were female, and the mean age was 61 (30–92) years. There were 582 LMs in 51 patients and 35 benign liver lesions in 20 (12 patients had only benign and 8 both benign and malignant lesions). Of the 582 LMs, 472 (81.1%) evidenced 18F-FDG uptake and 572 (98.2%) 68Ga-FAPI uptake. The diagnostic accuracies of 68Ga-FAPI PET/CT and 18F-FDG PET/CT were 98% and 82%, respectively (p < 0.001; McNemar test). When the LMs were compared, the maximum standardized uptake (SUVmax) value was significantly higher on 18F-FDG PET/CT than 68Ga-FAPI PET/CT (median: 6.0 vs. 5.4; p = 0.016). However, the LM-to-background ratio (TBR) was significantly higher on 68Ga-FAPI PET/CT than 18F-FDG PET/CT (median: 4.1 vs. 2.1; p < 0.001). Conclusion 68Ga-FAPI PET/CT detected more LMs than did 18F-FDG PET/CT, and TBR was significantly higher on 68Ga-FAPI PET/CT than 18F-FDG PET/CT.

Primäre und sekundäre Lebertumore – aus Sicht der Nuklearmedizin

“…Die hohe Sensitivität der FAPI-PET zur Bildgebung hepatischer Läsionen konnte auch bei sekundären Leberläsionen demonstriert werden. In einer retrospektiven Arbeit mit 51 Patienten mit insgesamt 582 Leberläsionen konnten in der FAPI-PET ( 68 Ga-DOTA-FAPI-04) 572 Läsionen (98,2%) detektiert werden, wohingegen in der FDG-PET lediglich 472 (81,1%) erkannt wurden [89]. Das Patientenkollektiv beinhaltete dabei 11 Patienten mit CRC, 9 Patienten mit Magenkarzinomen, 9 Patienten mit Lungenkarzinomen und 7 Patienten mit Mammakarzinomen.…”